Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis
| Author | Alessandro Federico | en |
| Author | Dolores Sgambato | en |
| Author | Gaetano Cotticelli | en |
| Author | Antonietta Gerarda Gravina | en |
| Author | Marcello Dallio | en |
| Author | Filippo Beneduce | en |
| Author | Eleonora Ruocco | en |
| Author | Marco Romano | en |
| Author | Carmela Loguercio | en |
| Issued Date | 2014-03-01 | en |
| Abstract | Introduction: Dermatological adverse events are an existing concern during treatment of hepatitis C virus infection. Peginterferon/ribavirin treatment is associated with well-characterized dermatological lesions tending towards a uniform entity of dermatitis. New telaprevir- or boceprevir-based triple-therapy has led to significant improvements in sustained virological response rates, although associated with an increase in cutaneous adverse events compared peginterferon/ribavirin alone. Case Presentation: We report a case of a patient who discontinued telaprevir because of severe skin eruptions and who, during ribavirin and interferon treatment, after a period free of skin lesions, developed new dermatological lesions different than those experienced during telaprevir treatment. Conclusions: Several adverse effects are associated to anti-HCV drugs, hence appropriate skin care management and follow-up are very important. A careful anamnesis before the initiation of triple therapy is necessary to identify previous dermatological diseases that could increase skin adverse effects incidence. | en |
| DOI | https://doi.org/10.5812/hepatmon.16632 | en |
| Keyword | Liver Cirrhosis | en |
| Keyword | Telaprevir | en |
| Keyword | Skin Diseases | en |
| Publisher | Brieflands | en |
| Title | Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis | en |
| Type | Case Report | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 15380-pdf.pdf
- Size:
- 441.34 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF